Scientists have demonstrated a relation between two types of heart problems and one of the most commonly prescribed classes of antibiotics for the first time.
As per a study published in the Journal of the American College of Cardiology, researchers at the University of British Columbia (UBC) in partnership with the Provincial Health Services Authority’s (PHSA) Therapeutic Evaluation Unit discovered that current users of fluoroquinolone antibiotics, such as Ciprofloxacin or Cipro, deal with a 2.4 times greater risk of developing aortic and mitral regurgitation, in which the blood backflows into the heart, contrary to patients who take amoxicillin, a different type of antibiotic. The most serious risk is within 30 days of use.
Recent studies have also classified the same type of antibiotics for linking to other heart problems.
Some physicians favor fluoroquinolones over other antibiotics for their wider effect of antibacterial activity and high oral absorption, which is as striking as intravenous, or IV, treatment.
This range of antibiotics is convenient, but for most of the cases, especially community-related infections, they’re not really required. The unnecessary prescribing may cause both antibiotic resistance as well as serious heart problems.
The researchers believe their study informs the public and physicians that if patients present with cardiac issues, where no other cause has been discovered, fluoroquinolone antibiotics could be a possible cause.
One of the main objectives of the Therapeutic Evaluation Unit is to assess different drugs and health technologies to find out whether they enhance the quality of care delivered by our programs or improve patient outcomes, said Dr. Bruce Carleton, director of the unit and research investigator at BC Children’s Hospital, a program of PHSA.
This study underlines the need to be thoughtful when prescribing antibiotics, which can sometimes cause harm.
To carry out the study, scientists analyzed data from the U.S. Food and Drug Administration’s adverse reporting system.
They also examined a huge private insurance health claims database in the U.S. that involves demographics, drug identification, dose prescribed and treatment duration. Researchers went through 12,505 cases of valvular regurgitation with 125,020 case-control subjects in a random sample of more than nine million patients. They stated current fluoroquinolone exposure as an active prescription or 30 days prior to the adverse event, recent exposure as within days 31 to 60, and past exposure as within 61 to 365 days prior to an incident.
Researchers discovered that the risk of aortic and mitral regurgitation, blood backflow into the heart, at rising with …read more
Source:: Daily Times